Home » Newsletters » BioWorld Science

BioWorld Science

April 27, 2005

View Archived Issues

Neuroprotective antiinflammatory effects of the MLK inhibitor CEP-1347 shown in vitro and in vivo

The potent antitumor candidate XR-5944 displays a unique mechanism of action

AGS-PSCA: a candidate for clinical trials in prostate, pancreatic cancers

Transgenomic to provide additional nucleic acid products to Geron

Second phase review in Europe of Johnson & Johnson's acquisition of Guidant

Japan Tobacco and Torii pharma production facilities to merge

Exelixis submits IND for XL-820

Orphan drug designation for doxorubicin Transdrug in primary liver cancer

ThromboView update

Alizyme completes thorough cardiovascular safety trial of renzapride

Japanese approval of biopharmaceutical using GroPep's Cell Culture Products

Enrollment completed in diabetes study of Diamyd in children

Phase IIb study of Hamilton's HL-0812 supported by Series A financing

Myriad presents new data on anticancer drug candidates MPC-2130 and MPC-6827

Recent patents describe therapeutic agents for asthma

New immunomodulatory agents disclosed by General Atomics

Novel agents for urinary incontinence and renal disorders imparted in recent patents

New data on the safety profile of 17-AAG in patients with solid tumors

Discovery and preclinical profile of dual VEGFR-2/FGFR-1 kinase inhibitors

PU-H58, a highly potent and selective Hsp90 inhibitor

Promising results reported for SGN-40 in recurrent multiple myeloma

Preclinical evidence supports the use of CYC-202 in multiple myeloma

Update on lenalidomide in multiple myeloma

MP4 safe in human volunteers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...